Malignant pleural mesothelioma (MPM) has a dismal prognosis. Treatment results may be improved by biomarker-directed therapy. We investigated the baseline expression and impact on outcome of predictive biomarkers ERCC1, BRCA1, and class III β-tubulin in a cohort of MPM patients treated with cisplatin-vinorelbine. We further explored the possibility of combining markers into a treatment-response profile to increase the predictive power.
Cancer Chemotherapy and Pharmacology, 2012, Vol 70, Issue 5, p. 743-54
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't